ERYTECH Pharma S.A. (NASDAQ:ERYP) Q2 2019 Earnings Conference Call Transcript
Sep 18, 2019 • 08:29 am ET
now shifting to the next slide. Slide number 13 for a snapshot of our cash utilization and cash position. As you can see, the cash position at the end of the first half of this year, June 30 was EUR94.5 million, which is approximately $107 million. That is coming from a cash valuation -- cash utilization in the first half of this year of EUR39.9 million. And that cash utilization was the result of a EUR40.5 million net cash utilization in operating, investing and financing activities, EUR23.8 million in operating activities, EUR17.6 million in investing activities, and EUR0.8 million in financing activities.
And in the same time, with the appreciation of the US dollar in the period against the euro, we had EUR0.6 million favorable currency exchange impact on the cash position. With that, that's enabled us to confirm the earlier guidance we've given on the cash runway, which is getting us until the end of 2020, possibly into 2021. That's the highlight for the cash position and cash utilization.
And before we finish this presentation and open the Q&A session, just reminding the key milestones for the next 12 month period. Of course, Gil mentioned it earlier, the start of our GMP production facility in Princeton expected in Q4 this year very imminently that will enable the start of the US patient enrolment in the Phase III clinical trial for the second line pancreatic cancer trial that's the TRYbeCA1 study, which is also expected in Q4 to start.
And we also mentioned, well that's for the 2020 periods the initiation of the Phase 1 investing -- investigator sponsored study with eryaspase in pancreatic cancer for the first line treatments and later in 2020, we expect the results of the Phase II second-line trial in acute lymphoblastic leukemia, the NOPHO study, also an IST study. And finally, towards the mid-year period of next year, we would expect the interim analysis into TRYbeCA1 study, again the Phase III in pancreatic cancer that interim analysis is for superiority.
With that, I will turn over the call to Shannon, our operator to open the Q&A session. Thank you.